Stereotaxis, Inc. 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Stereotaxis, Inc.
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: Stereotaxis designs, manufactures, and markets the NIOBE System, an advanced cardiology instrument control system that uses magnetic fields to remotely navigate catheters and guidewires for treating arrhythmias and coronary artery disease. The company also markets the ODYSSEY information management system and various disposable interventional devices.
Key Milestones: As of December 31, 2007, the company had sold and delivered 93 NIOBE Systems. The company maintains strategic alliances with Siemens AG, Philips Medical Systems, and Biosense Webster for integration, sales, and service.
Key Financial Metrics
| Metric (in thousands) | 2007 | 2006 |
|---|---|---|
| Total Revenue | $39,299 | $27,192 |
| Gross Margin | $23,953 (61.0%) | $14,299 (52.6%) |
| Operating Loss | $(49,242) | $(46,671) |
| Net Loss | $(48,122) | $(45,720) |
| Cash and Short-term Investments | $23,656 | $36,984 |
| Working Capital | $21,926 | $40,384 |
| Long-term Debt | $6,000 | $306 |
Note: Gross margin percentage excludes a $1.9 million inventory impairment charge related to the first-generation NIOBE system recorded in 2007.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 45% to $39.3 million, driven by a 33% increase in system sales (27 systems sold in 2007 vs. 23 in 2006) and a 102% increase in revenue from disposables, service, and accessories.
- Expense Increases: Operating expenses rose to $73.2 million from $61.0 million. Research and Development (R&D) increased 17% to $25.5 million, and Sales and Marketing increased 29% to $29.0 million due to hiring and expanded programs.
- Inventory Impairment: A non-cash charge of $1.9 million was recorded in Cost of Revenue for the write-down of first-generation NIOBE system inventory.
- Liquidity: Cash and short-term investments decreased by approximately $13.3 million, primarily due to operating losses and reduced investment balances, though the company raised $20.1 million in net proceeds from a stock offering in March 2007.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to incur additional losses in 2008 as it continues product development and commercialization. The company projects it will be positioned to achieve break-even operating performance by the end of 2009.
- Backlog: As of December 31, 2007, the company had approximately $58 million in backlog. Management does not expect more than 50% of this backlog to be recognized as revenue in 2008 due to lengthy sales cycles and installation contingencies.
- Unusual Item (Product Issue): In March 2008, the company announced a temporary halt in procedures using its partnered magnetic irrigated catheter due to signs of char or coagulum formation. The partner attributed this to manufacturing conformance issues. Full commercialization is delayed until resolved.
- Liquidity Risk: The company expects negative cash flow from operations through 2008. It relies on existing cash resources and a $25 million working capital line of credit (amended in February 2008 to $30 million with shareholder guarantees) to fund operations.
- Investment Risk: The company held $500,000 in auction rate securities (ARS) at year-end. Due to liquidity issues in the ARS market in early 2008, the company may be unable to liquidate these holdings at par or may need to reclassify them as long-term assets.
Key Facts for Investor Verification
- Profitability Timeline: Verify the feasibility of the management's projection to reach break-even operations by the end of 2009 given the current burn rate and backlog recognition rates.
- Catheter Resolution: Monitor the status of the magnetic irrigated catheter issue announced in March 2008 and its impact on future revenue from disposables.
- Liquidity Position: Assess the sufficiency of the $23.7 million in cash/investments and the $30 million credit facility to sustain operations through 2008 without further dilutive financing.
- Backlog Conversion: Track the actual revenue recognition from the $58 million backlog, noting the risk of order cancellations or delays due to hospital construction cycles.
- Auction Rate Securities: Confirm the liquidity status and potential impairment of the $500,000 ARS holding in light of market conditions.